CXorf56

Across TCGA pan-cancer cohorts, CXorf56 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CXorf56 data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CXorf56 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CXorf56 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where CXorf56 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.291	1.000	.001	45	view →
LSCC	DFS	Tertile	II,III,IV	0.949	0.433	<.001	43	view →
LUAD	OS	Tertile	III,IV	0.848	0.317	.004	39	view →
GBM	OS	Tertile	All	0.696	0.386	.001	15	view →
PDAC	OS	Tertile	IV	0.916	0.231	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CXorf56–HNSC (DFS)

Open the HNSC breakdown →